{"product_id":"enzyme-inhibition-in-drug-discovery-and-development-9780470281741","title":"Enzyme Inhibition in Drug Discovery and Development","description":"The science and applied approaches of enzyme inhibition in drug discovery and development \u003cp\u003eOffering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, \u003ci\u003eEnzyme Inhibition in Drug Discovery and Development\u003c\/i\u003e examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development.\u003c\/p\u003e \u003cp\u003eWith chapters written by over fifty leading experts in their fields, \u003ci\u003eEnzyme Inhibition in Drug Discovery and Development\u003c\/i\u003e fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the \"good\" inhibitions--desirable pharmacological effects--and \"bad\" inhibitions--drug-drug interactions and toxicity. The book discusses: \u003c\/p\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eThe drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eThe manipulations of drug metabolizing enzymes and transporters as well as the negative consequences, such as drug-drug interactions\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eThe inhibition of several major drug target pathways, such as the GPCR pathway, the NFkB pathway, and the ion channel pathway\u003c\/p\u003e \u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThrough this focused, single-source reference on the fundamentals of drug discovery and development, researchers in drug metabolism and pharmacokinetics (DMPK) will learn and appreciate target biology in drug discovery; discovery biologists and medicinal chemists will also broaden their understanding of DMPK.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eAuthor:\u003c\/b\u003e Chuang Lu\u003cbr\u003e\u003cb\u003ePublisher:\u003c\/b\u003e Wiley\u003cbr\u003e\u003cb\u003ePublished:\u003c\/b\u003e 01\/01\/2010\u003cbr\u003e\u003cb\u003ePages:\u003c\/b\u003e 876\u003cbr\u003e\u003cb\u003eBinding Type:\u003c\/b\u003e Hardcover\u003cbr\u003e\u003cb\u003eWeight:\u003c\/b\u003e 2.80lbs\u003cbr\u003e\u003cb\u003eSize:\u003c\/b\u003e 9.30h x 6.30w x 1.70d\u003cbr\u003e\u003cb\u003eISBN:\u003c\/b\u003e 9780470281741\u003cbr\u003e\u003cbr\u003e\u003cb\u003eReview Citation(s): \u003c\/b\u003e\u003cbr\u003e\u003ci\u003eScitech Book News\u003c\/i\u003e 03\/01\/2010 pg. 61\u003cbr\u003e\u003cp\u003e\u003cb\u003eAbout the Author\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eChuang Lu, PhD\u003c\/b\u003e, is the Associate Director in the Drug Safety and Disposition Department of Millennium Pharmaceuticals. His current research interests include drug-metabolizing enzymes, drug-drug interaction, and in vitro-in vivo correlation. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eAlbert P. Li, PhD\u003c\/b\u003e, is the President and CEO of In Vitro ADMET Laboratories, LLC and Advanced Pharmaceutical Sciences, Inc., and the cofounder, Chairman, and CSO of the ADMET Group. His experience spans over twenty-five years in the drug development industry, with over 150 publications. He is the editor of several books, including \u003ci\u003eDrug-Drug Interactions in Pharmaceutical Development\u003c\/i\u003e, published by Wiley.\u003c\/p\u003e\u003cbr\u003e","brand":"Wiley","offers":[{"title":"Hardcover","offer_id":40905230352499,"sku":"9.78047E+12","price":380.3,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0555\/9255\/0515\/products\/img_28e7cdb2-9e6c-48cc-9b35-8eec24b01a1e.jpg?v=1690894926","url":"https:\/\/bookstorenmore.com\/products\/enzyme-inhibition-in-drug-discovery-and-development-9780470281741","provider":"Bookstore N More","version":"1.0","type":"link"}